Graftys : initiation of post Marketing Surveillance program

Orega_actu
OREGA announces licensing of its first in class CD39 checkpoint inhibitor
10 January 2016
AlizeePharma_actu
Alize reports positive clinical results
29 October 2015

Graftys : initiation of post Marketing Surveillance program

Graphtys_actu

The international registry will include patients who received implants of GRAFTYS® HBS and QuickSet.